Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jul 29 2010 Cyclacel Pharmaceuticals to announce release of second quarter 2010 financial results Jul 01 2010 Cyclacel Pharmaceuticals announces FDA orphan drug designation for sapacitabine in both AML and MDS Jun 28 2010 Cyclacel Pharmaceuticals added to Russell Microcap Index Jun 18 2010 Cyclacel answers Celgene’s declaratory judgment complaint and counterclaims for infringement of four Cyclacel patents Jun 07 2010 Cyclacel reports interim Phase 2 sapacitabine data in myelodysplastic syndromes at 2010 ASCO annual meeting May 21 2010 Cyclacel Pharmaceuticals to report new sapacitabine Phase 2 interim results in MDS at the American Society of Clinical Oncology Annual Meeting May 13 2010 Cyclacel Pharmaceuticals reports financial results for first quarter 2010 May 13 2010 Cyclacel to restate 2009 annual financial statements to correct net loss per share May 07 2010 Cyclacel to announce release of first quarter 2010 financial results and upcoming corporate events Apr 30 2010 Cyclacel receives complaint filed by Celgene seeking to avoid certain Cyclacel patents Apr 20 2010 Cyclacel's innovative and diverse oncology targeted pipeline highlighted in six presentations at AACR Annual Meeting Apr 01 2010 Cyclacel announces multiple abstracts selected for presentation at American Association for Cancer Research Annual Meeting Mar 23 2010 Cyclacel Pharmaceuticals reports fourth quarter and full year 2009 financial results Mar 17 2010 Cyclacel Pharmaceuticals to announce fourth quarter 2009 financial results on March 23, 2010 Mar 08 2010 Cyclacel Pharmaceuticals to present at the 22nd annual ROTH Capital OC Growth Stock Conference Feb 17 2010 New Study in CCR demonstrates potential for seliciclib in treating breast cancer resistant to hormone therapy Feb 01 2010 Cyclacel Pharmaceuticals to present at the 12th Annual BIO CEO & Investor Conference Jan 27 2010 Cyclacel regains NASDAQ compliance Jan 25 2010 Cyclacel completes previously announced registered direct offering Jan 21 2010 Cyclacel to raise up to $7.9 million in registered direct offering Jan 13 2010 Cyclacel completes previously announced registered direct offering Jan 11 2010 Cyclacel to raise up to $9.5 million in registered direct offering Jan 07 2010 Cyclacel’s seliciclib found effective against lung cancer cell Lines including K-RAS mutations Jan 06 2010 Cyclacel Pharmaceuticals to present at OneMedForum 2010 Dec 30 2009 Cyclacel announces publication of peer-reviewed journal article describing the mechanism of action of seliciclib Pagination First page « first Previous page ‹ previous … Page 11 Page 12 Page 13 Page 14 Current page 15 Page 16 Page 17 Page 18 Page 19 … Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Jul 29 2010 Cyclacel Pharmaceuticals to announce release of second quarter 2010 financial results Jul 01 2010 Cyclacel Pharmaceuticals announces FDA orphan drug designation for sapacitabine in both AML and MDS Jun 28 2010 Cyclacel Pharmaceuticals added to Russell Microcap Index Jun 18 2010 Cyclacel answers Celgene’s declaratory judgment complaint and counterclaims for infringement of four Cyclacel patents Jun 07 2010 Cyclacel reports interim Phase 2 sapacitabine data in myelodysplastic syndromes at 2010 ASCO annual meeting May 21 2010 Cyclacel Pharmaceuticals to report new sapacitabine Phase 2 interim results in MDS at the American Society of Clinical Oncology Annual Meeting May 13 2010 Cyclacel Pharmaceuticals reports financial results for first quarter 2010 May 13 2010 Cyclacel to restate 2009 annual financial statements to correct net loss per share May 07 2010 Cyclacel to announce release of first quarter 2010 financial results and upcoming corporate events Apr 30 2010 Cyclacel receives complaint filed by Celgene seeking to avoid certain Cyclacel patents Apr 20 2010 Cyclacel's innovative and diverse oncology targeted pipeline highlighted in six presentations at AACR Annual Meeting Apr 01 2010 Cyclacel announces multiple abstracts selected for presentation at American Association for Cancer Research Annual Meeting Mar 23 2010 Cyclacel Pharmaceuticals reports fourth quarter and full year 2009 financial results Mar 17 2010 Cyclacel Pharmaceuticals to announce fourth quarter 2009 financial results on March 23, 2010 Mar 08 2010 Cyclacel Pharmaceuticals to present at the 22nd annual ROTH Capital OC Growth Stock Conference Feb 17 2010 New Study in CCR demonstrates potential for seliciclib in treating breast cancer resistant to hormone therapy Feb 01 2010 Cyclacel Pharmaceuticals to present at the 12th Annual BIO CEO & Investor Conference Jan 27 2010 Cyclacel regains NASDAQ compliance Jan 25 2010 Cyclacel completes previously announced registered direct offering Jan 21 2010 Cyclacel to raise up to $7.9 million in registered direct offering Jan 13 2010 Cyclacel completes previously announced registered direct offering Jan 11 2010 Cyclacel to raise up to $9.5 million in registered direct offering Jan 07 2010 Cyclacel’s seliciclib found effective against lung cancer cell Lines including K-RAS mutations Jan 06 2010 Cyclacel Pharmaceuticals to present at OneMedForum 2010 Dec 30 2009 Cyclacel announces publication of peer-reviewed journal article describing the mechanism of action of seliciclib Pagination First page « first Previous page ‹ previous … Page 11 Page 12 Page 13 Page 14 Current page 15 Page 16 Page 17 Page 18 Page 19 … Next page next › Last page last »
Jul 01 2010 Cyclacel Pharmaceuticals announces FDA orphan drug designation for sapacitabine in both AML and MDS
Jun 18 2010 Cyclacel answers Celgene’s declaratory judgment complaint and counterclaims for infringement of four Cyclacel patents
Jun 07 2010 Cyclacel reports interim Phase 2 sapacitabine data in myelodysplastic syndromes at 2010 ASCO annual meeting
May 21 2010 Cyclacel Pharmaceuticals to report new sapacitabine Phase 2 interim results in MDS at the American Society of Clinical Oncology Annual Meeting
May 07 2010 Cyclacel to announce release of first quarter 2010 financial results and upcoming corporate events
Apr 20 2010 Cyclacel's innovative and diverse oncology targeted pipeline highlighted in six presentations at AACR Annual Meeting
Apr 01 2010 Cyclacel announces multiple abstracts selected for presentation at American Association for Cancer Research Annual Meeting
Mar 17 2010 Cyclacel Pharmaceuticals to announce fourth quarter 2009 financial results on March 23, 2010
Mar 08 2010 Cyclacel Pharmaceuticals to present at the 22nd annual ROTH Capital OC Growth Stock Conference
Feb 17 2010 New Study in CCR demonstrates potential for seliciclib in treating breast cancer resistant to hormone therapy
Jan 07 2010 Cyclacel’s seliciclib found effective against lung cancer cell Lines including K-RAS mutations
Dec 30 2009 Cyclacel announces publication of peer-reviewed journal article describing the mechanism of action of seliciclib
